MX2013006116A - Tratamiento de sintomas asociados a placa amiloide. - Google Patents
Tratamiento de sintomas asociados a placa amiloide.Info
- Publication number
- MX2013006116A MX2013006116A MX2013006116A MX2013006116A MX2013006116A MX 2013006116 A MX2013006116 A MX 2013006116A MX 2013006116 A MX2013006116 A MX 2013006116A MX 2013006116 A MX2013006116 A MX 2013006116A MX 2013006116 A MX2013006116 A MX 2013006116A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- seq
- amino acid
- apoe
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41906010P | 2010-12-02 | 2010-12-02 | |
| US201161548542P | 2011-10-18 | 2011-10-18 | |
| PCT/US2011/063121 WO2012075422A2 (en) | 2010-12-02 | 2011-12-02 | Compositions and methods for treating amyloid plaque associated symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013006116A true MX2013006116A (es) | 2013-10-17 |
Family
ID=46172597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013006116A MX2013006116A (es) | 2010-12-02 | 2011-12-02 | Tratamiento de sintomas asociados a placa amiloide. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20140037638A1 (enExample) |
| EP (1) | EP2646053A4 (enExample) |
| JP (1) | JP2014502276A (enExample) |
| KR (1) | KR20140017513A (enExample) |
| CN (1) | CN103338786A (enExample) |
| AU (1) | AU2011336360A1 (enExample) |
| BR (1) | BR112013013723A2 (enExample) |
| CA (1) | CA2819679A1 (enExample) |
| MX (1) | MX2013006116A (enExample) |
| NZ (1) | NZ611614A (enExample) |
| RU (1) | RU2013130002A (enExample) |
| SG (1) | SG190952A1 (enExample) |
| WO (1) | WO2012075422A2 (enExample) |
| ZA (1) | ZA201303996B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2847218A4 (en) * | 2012-05-08 | 2015-12-30 | Univ Ramot | APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| US10830775B2 (en) | 2014-09-30 | 2020-11-10 | Washington University | Tau kinetic measurements |
| WO2017192711A1 (en) * | 2016-05-03 | 2017-11-09 | University Of South Florida | Compositions and methods of modulating abeta protein |
| US11124562B2 (en) | 2016-10-28 | 2021-09-21 | Washington University | Anti-ApoE antibodies |
| JP7280238B2 (ja) * | 2017-07-17 | 2023-05-23 | ヤンセン バイオテツク，インコーポレーテツド | フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法 |
| AU2020282792B2 (en) * | 2019-05-28 | 2025-12-04 | Banner Health | ApoE antibodies, fusion proteins and uses thereof |
| WO2023069892A1 (en) * | 2021-10-19 | 2023-04-27 | Short Jay M | Conditionally active proteins for neurodegenerative diseases |
| JP2025540077A (ja) * | 2022-11-30 | 2025-12-11 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | ナチュラルキラー細胞エンゲージャー |
| WO2026019667A1 (en) * | 2024-07-17 | 2026-01-22 | Jn Biosciences Llc | Trispecific antibodies for activation of immune cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994009155A1 (en) * | 1992-10-13 | 1994-04-28 | Duke University | Methods of detecting alzheimer's disease |
| GB2408508A (en) * | 2003-11-28 | 2005-06-01 | Astrazeneca Ab | Apolipoprotein antibodies |
| AU2005228764A1 (en) * | 2004-03-30 | 2005-10-13 | Renomedix Institute Inc. | Remedy for prion disease and method of producing the same |
| WO2007098417A2 (en) * | 2006-02-21 | 2007-08-30 | Oklahoma Medical Research Foundation | Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor |
| CA2672581A1 (en) * | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same |
| CL2008002775A1 (es) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| WO2011109246A1 (en) * | 2010-03-01 | 2011-09-09 | The J. David Gladstone Institutes | Antibody specific for apolipoprotein and methods of use thereof |
-
2011
- 2011-12-02 KR KR1020137016719A patent/KR20140017513A/ko not_active Withdrawn
- 2011-12-02 MX MX2013006116A patent/MX2013006116A/es not_active Application Discontinuation
- 2011-12-02 NZ NZ611614A patent/NZ611614A/en not_active IP Right Cessation
- 2011-12-02 WO PCT/US2011/063121 patent/WO2012075422A2/en not_active Ceased
- 2011-12-02 SG SG2013042288A patent/SG190952A1/en unknown
- 2011-12-02 US US13/990,777 patent/US20140037638A1/en not_active Abandoned
- 2011-12-02 RU RU2013130002/10A patent/RU2013130002A/ru not_active Application Discontinuation
- 2011-12-02 JP JP2013542218A patent/JP2014502276A/ja active Pending
- 2011-12-02 EP EP11844128.6A patent/EP2646053A4/en not_active Withdrawn
- 2011-12-02 BR BR112013013723A patent/BR112013013723A2/pt not_active IP Right Cessation
- 2011-12-02 CA CA2819679A patent/CA2819679A1/en not_active Abandoned
- 2011-12-02 AU AU2011336360A patent/AU2011336360A1/en not_active Abandoned
- 2011-12-02 CN CN2011800667946A patent/CN103338786A/zh active Pending
-
2013
- 2013-05-31 ZA ZA2013/03996A patent/ZA201303996B/en unknown
-
2016
- 2016-08-22 US US15/243,495 patent/US20160355581A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201303996B (en) | 2015-10-28 |
| NZ611614A (en) | 2015-07-31 |
| US20140037638A1 (en) | 2014-02-06 |
| US20160355581A1 (en) | 2016-12-08 |
| EP2646053A4 (en) | 2014-05-28 |
| WO2012075422A2 (en) | 2012-06-07 |
| RU2013130002A (ru) | 2015-01-10 |
| JP2014502276A (ja) | 2014-01-30 |
| CN103338786A (zh) | 2013-10-02 |
| WO2012075422A3 (en) | 2012-10-04 |
| SG190952A1 (en) | 2013-07-31 |
| AU2011336360A1 (en) | 2013-07-04 |
| CA2819679A1 (en) | 2012-06-07 |
| BR112013013723A2 (pt) | 2019-09-24 |
| KR20140017513A (ko) | 2014-02-11 |
| EP2646053A2 (en) | 2013-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20160355581A1 (en) | Compositions and methods for treating amyloid plaque associated symptoms | |
| AU2006319358B2 (en) | Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies | |
| CA2633399C (en) | Therapeutic vaccine | |
| TWI516500B (zh) | 抗β類澱粉蛋白單株抗體 | |
| US8105594B2 (en) | Methods for amyloid removal using anti-amyloid antibodies | |
| KR100701580B1 (ko) | 항-아밀로이드 항체를 이용한 아밀로이드 제거 방법들 | |
| US20140050733A1 (en) | Apoe immunotherapy | |
| CA2761665A1 (fr) | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide | |
| KR20100097651A (ko) | 베타-아밀로이드 펩티드에 특이적인 신규 항체 및 진단제 또는 진단약으로서의 그 용도 | |
| US20140127225A1 (en) | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition | |
| CN114430744A (zh) | 抗Tau抗体及其用途 | |
| US12509512B2 (en) | Semaphorin 3A antibodies and uses thereof | |
| Solomon et al. | Immunotherapy for Alzheimer’s disease | |
| AU2003262458B2 (en) | Methods for amyloid removal using anti-amyloid antibodies | |
| MX2008007149A (en) | Therapeutic vaccine | |
| HK40005250A (en) | Compositions and methods for treating spinal muscular atrophy | |
| NZ623275B2 (en) | Treatment of ocular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |